Results from the phase 3 AWARD-11 trial evaluating higher doses of dulaglutide showed superior HbA1c and body weight reductions with an investigational 4.5mg dose in patients with type 2 diabetes (T2D) compared with dulaglutide 1.5mg.
All articles by Brian Park, PharmD
The FDA has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome.
Publish Date
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 against the approval of empagliflozin 2.5 mg as an adjunct to insulin for adults with type 1 diabetes.
Publish Date
-
Latest News Your top articles for Sunday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses